Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ahnjeonbaekho-tang (AJBHT) is a traditional Korean herbal medicine (Hanbang) formulation developed as an alternative therapy for Graves' disease, particularly for patients who experience adverse side effects from conventional antithyroid drugs such as methimazole (MMI) and propylthiouracil (PTU). AJBHT is a modified version of the classical 'Baekho-tang' formula. Mechanistically, it suppresses thyroid hormone synthesis by inhibiting the production of cyclic adenosine monophosphate (cAMP) and the expression of thyroglobulin (Tg) mRNA in thyroid cells. Clinical studies have demonstrated that treatment with AJBHT leads to a significant reduction in serum triiodothyronine (T3) and free thyroxine (FT4) levels, accompanied by an increase in thyroid-stimulating hormone (TSH) levels, thereby helping to normalize thyroid function in hyperthyroid patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ahnjeonbaekho-tang.